ImmuDyne Signs Non-Binding Term Sheet for Exclusive Rights to Dermatologist Backed Hair Loss Product
July 12 2016 - 9:24AM
-ImmuDyne signs non-binding term sheet to in-license disruptive,
dermatologist-backed hair loss product with definitive agreement
expected in August-Company preparing for an expected global product
launch online and in leading retail stores in Q4’16
ImmuDyne (OTCQB:IMMD), a leader in the development and marketing of
OTC healthcare products, today announced the signing of a
non-binding term sheet with Pilaris Laboratories, LLC, for an
exclusive worldwide license to commercialize the PilarisMax line of
hair loss products.
Pilaris Laboratories (“Pilaris”) was founded by Dermatologists
Steven D. Shapiro M.D. and Michael T. Borenstein M.D. Ph.D. after 5
years of clinical research on topical dihydrotestosterone (DHT)
inhibitors. Dr. Shapiro has 27 years of clinical experience
with treating hair loss and hair transplant procedures. Dr.
Borenstein holds a PhD in Pharmacology and has a background in
scientific research and clinical dermatology.
Pilaris Laboratories’ lead product is a shampoo with three
potent naturally occurring DHT blockers in an innovative sulfate
free base that has shown to be safe and effective in supporting
hair health and thickness in both men and women. Pilaris
Laboratories and Immudyne will immediately begin work on developing
a conditioner with a complimentary ingredient profile.
“We are thrilled to partner with Dr. Shapiro and Dr. Borenstein
on the global launch of an innovative, breakthrough product aimed
at helping millions of men and women that struggle with thinning
hair,” stated Mark McLaughlin, President & CEO of
Immudyne. “After a thorough due diligence process and
independent product testing, Immudyne’s leadership and scientific
team believe Pilaris’ solution may be superior to currently
marketed products in the hair loss category, and could become a
successful global brand under the leadership of Immudyne PR, our
direct marketing division.
“Our goal as physicians and scientists has been to find a
marketing partner with integrity and a successful track record in
the direct marketing space,” stated Michael Borenstein, M.D., PhD,
“We feel ImmuDyne is the right partner to get our products in the
hands of men and women around the world that want a safe and
effective product for hair loss.”
According to www.ibisworld.com, the hair loss treatment market
is estimated to be $3.5 billion per year worldwide.
Immudyne expects to execute a Definitive Licensing Agreement
with Pilaris Laboratories in August and has already commenced
preparing for launch of the product online.
About ImmuDyne, Inc.
ImmuDyne, Inc. (the “Company”) develops, manufactures and sells
natural immune support products containing the Company’s
proprietary yeast beta glucans. The Company also has a
majority owned direct marketing division that markets immune
support, skincare and hair loss products directly to consumers
around the world. All of ImmuDyne’s intellectual property is
protected by patents and/or trade secrets. Additional information
can be found on the web at www.immudyne.com.
Forward-Looking Statements
Cautionary language regarding Forward-Looking Statements Safe
Harbor Act Disclaimer: Forward-looking statements in this release
are made pursuant to the Safe Harbor Provisions of the Private
Securities Litigation Reform Act of 1995. Certain statements in
this press release, including projections with respect to
ImmuDyne’s results of operations, may contain words such as
"anticipates," "believes," "could," "estimates," "expects,"
"intends," "may," "projects," "plans," "targets" and other similar
language and are considered forward-looking statements. These
statements are based on management's current expectations,
estimates, and forecasts. These forward-looking statements are
subject to important assumptions, risks and uncertainties, which
are difficult to predict and therefore the actual results may be
materially different from those discussed.
Contact:
ImmuDyne, Inc.
Mark McLaughlin: +1-914-714-8901